



### PROGRAMME OVERVIEW

update November 21, 2022

**November 24, 2022**

**Venue: CORPUS CONGRESS CENTRE - Oegstgeest  
the Netherlands**

## *‘Innovations and new business strategies in Dutch Life Sciences’*

The Dutch Life Sciences & Health industry includes nowadays 3100 R&D life Sciences companies and 420 biopharmaceutical companies. Together with 13 universities and 8 university medical centres the industry is constantly innovating when it comes to research and development. Behind this lies the convergence of science and technology, leading a new era of healthcare, and an unprecedented growth in innovation and business. The conference showcases the latest innovations and young companies that apply new business strategies to bring these innovations to patient.

07:45      **Registration desks open breakfast sessions**

---

08:00      **CxO breakfast meeting:** for CEOs, CFOs, COOs and CBOs active in the life sciences sector  
*The Dutch Life Sciences conference will start with a breakfast session which is organised in collaboration with The Entrepreneurs Association Bio Science Park.  
The Breakfast try to spur informal networking so that people can build stronger networks and help identify opportunities and individuals they can work with to advance ideas. During the breakfast new members of the Leiden Bio Science Park business community will introduce themselves.*

*Limited places are available and only to MT members from (R&D) life sciences companies who are attending the conference.*

08:00      **Investors forum part 1 - breakfast session -**  
hosted by 

INNOVATION

**MODERATOR: Dr. Harrold van Barlingen, Managing Partner at Thuja Capital**

*The investors forum is an exciting opportunity for those companies looking for equity capital and/or partnerships with companies and institutes across the life sciences value chain, from biotech, medtech and pharma companies to financiers and universities. The forum offers excellent opportunities for presenting your company or university to Venture Capitalists, corporate- and regional investment funds and to discuss your business strategy.*




08:45      **Registration desk, exhibition open**

---

09:30-10:50 **Plenary morning programme**

hosted by



- 09:30      **Welcome by moderator Eveline van Rijswijk**  
*Eveline is a science journalist with experience in communicating science on television, radio, online and during events and conferences.*
- 09:35      **Opening by Hans Schikan PharmD, Member Topteam Dutch Top Sector for Life Sciences and Health**
- 09:45      **‘Fundraising- , M&A- and spin-off trends in the Life Sciences industry’**  
Jan De Kerpel, Managing Director at Kempen & Co. - Life Sciences & Healthcare  
  
*Jan De Kerpel will provide insights into the public market and M&A trends in the life sciences sector, more specifically from the areas covered during the breakout sessions including digital health, supply chain, mRNA therapeutics and regenerative medicines. Insights are also presented on the Life Sciences spin-offs that were established in 2021.*
- 10:15      Panel discussion with **Hans Schikan** (member Topteam Dutch Top Sector for Life Sciences & Health), **Bas Reichert** (chairman OVBS Leiden BioSciencePark) and **Kinga Matuła**, CEO & Co-founder CurieGen in which the entrepreneurial climate in Dutch Life Sciences will be discussed.
- 10:30      **Venture Challenge**  
hosted by   
  
*The winner of the Venture Challenge Fall 2022 will be announced!*  
Presentation by **Dr.ir. Chrétien Herben**, Program Director Life Sciences@Work
- 10:50      **Break**  
Exhibition open
-



11:30-12:45 Parallel morning sessions

<p><b>Digital Healthcare: lessons learned and challenges ahead</b></p> <p>Hosted by </p> <p>Moderator: Igor Excelmans</p>	<p>As digital technologies are getting embedded into our lives, their role in healthcare is rapidly being explored. The challenge however is to see how these emerging technologies can be implemented in the current regulatory framework and the upcoming regulatory framework for those technologies. In this session an overview is being presented about the digital health landscape as well as examples of two business strategies by which emerging technologies are being implemented.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Igor Excelmans</b> Pharmaceutical Consultant QbD</li> <li>▪ <b>ir. Holger Willems</b> Co-Founder &amp; CEO Relu</li> <li>▪ <b>Dr. Paul van de Wiel</b> CEO InnoSIGN</li> </ul>
<p><b>Supply chain challenges and strategies</b></p> <p>Hosted by </p> <p>Moderator: Erik Agterhuis</p>	<p>Rising costs and material shortages have impacted the pharmaceutical and life sciences industry supply chains. With pharmaceutical and life sciences supply chains, though, come even more complexities and challenges that must be overcome. In this session the developments, trends and solutions for the challenges are being addressed from medical devices and biopharmaceutical perspectives.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Drs. Erik Agterhuis</b>, Owner &amp; Founder Life Cell Science Supply Chain Consultancy: Dedicated to Biotech &amp; ATMP</li> <li>▪ <b>Peter Jones</b> Business Consultant QAD</li> <li>▪ <b>Nils Demanet</b> Commercial Lead Health &amp; Life Sciences and <b>Quentin Braet</b> Architecture Lead at In The Pocket</li> </ul>
<p><b>Spin-out strategies</b></p> <p>Hosted by </p> <p>Moderator: Carine van den Brink</p>	<p>Knowledge valorisation to the commercial sector for economic- and patients benefit is a key factor in innovation. Universities play an important role in the creation and development of knowledge and growth of the Dutch Life Sciences industry. Despite this success there are still obstacles in practice for a faster valorisation of new technologies. During this session these obstacles that young entrepreneurs are facing in practice and solutions for improving the valorisation process are being discussed. How to implement good social response licensing principles?, will standardisation of the process between academic institutes make valorisation paths quicker? How will the new Biotech Biobooster program support young entrepreneurs in their ambition to start and growth a life sciences company for patients benefit. Next to presentations the topic will also be addressed in a panel discussion from different perspectives.</p>	<p>Speakers and panellists:</p> <ul style="list-style-type: none"> <li>▪ <b>Ivo de Nooijer</b> Owner AMLUG</li> <li>▪ <b>Annemiek Verkamman</b> Managing Director HollandBIO</li> <li>▪ <b>Marc van Moorsel</b> Co-founder &amp; Chief Operating Officer TargED Biopharmaceuticals</li> <li>▪ <b>Rianne Ellenbroek</b> Investment Manager FIRST fund BioGeneration Ventures</li> </ul>





12:45-14:00 **Lunch, networking** > exhibition open

13:00 **Investors forum part 2 - lunch session –**

hosted by **Johnson & Johnson**

INNOVATION


14:00-15:15 **Parallel afternoon sessions**

<p><b>RNA therapeutics: scientific breakthroughs, challenges and business strategies</b></p> <p>Hosted by</p>  <p>Moderator: Dr. Ilse Roodink</p>	<p>RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize personalized medicine. It is a disruptive therapeutic technology, as small biotech startups, as well as academic groups, can rapidly develop new and personalized RNA construct.</p> <p>In this session an overview is provided of the RNA-based therapies that are currently being evaluated in clinical trials or have already received regulatory approval. Furthermore, the challenges associated with use of RNA-based drugs are also discussed as well as new innovations and commercialization strategies of two companies.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Rob Collin</b> Professor Molecular Therapies for Inherited Retinal Diseases Radboudumc</li> <li>▪ <b>Dr. Eric van der Veer</b> Chief Scientific Officer Hybridize Therapeutics</li> <li>▪ <b>Sander van Asbeck MSc</b> CEO RiboPro</li> </ul>
<p><b>Regenerative medicines: bringing regenerative technology of the future to patients today</b></p> <p>Hosted by</p>  <p>Moderator: Drs Petra Van Zuijlen RA</p>	<p>Regenerative medicine comprises various novel approaches to health care, representing a complex and heterogenous group of products, including those based on cell and gene therapy. The global regenerative medicine market size was valued at USD 27.29 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 11.27% from 2021 to 2027. Key companies invest heavily in the development of regenerative therapies to meet the demand for unmet clinical needs. In this session RegMedXB will explain how companies and research institutes work together in accelerating technology- and product development, and the creation of new ventures. Two companies will present their innovations and business strategies.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Peter de Haan</b> CSO and co-founder Amarna Therapeutics</li> <li>▪ <b>Tol Trimborn</b> CEO CellPoint</li> <li>▪ <b>Bernard Mulder, MD MBA</b> General Director Regmed XB</li> </ul>





## Continue parallel afternoon sessions

<p><b>Towards the production of your first medicinal product</b></p> <p>Hosted by</p>  <p>Moderator: Edwin van den Bos</p>	<p>The global life sciences portfolio of today reflects increased therapeutic competition, a greater prevalence of large molecule drugs, expansion of the number of personalized or targeted products, and a rise of treatments for many orphan diseases. All these companies have to make a choice about their strategy of producing their first medicinal product. Build their own production facilities or outsourcing to a contract manufacturing organisation (CMO). In this session the drivers for making this business decision as well as the pros and cons of the different strategies are being discussed. Two Life Sciences product companies will give insights in their journey towards the production of their first product.</p>	<p>Presentations by:</p> <ul style="list-style-type: none"> <li>▪ <b>Frank van Engelenburg</b> Managing Consultant Progress</li> <li>▪ <b>Lex Bakker PhD</b> EVP, Chief Development Officer Merus NV</li> <li>▪ <b>Markwin Velders</b> Managing Director Prime Life Science</li> </ul>
--	--	--

15:15 **Break, networking > exhibition open**

---

16:00 **Wrap up conference**

---

16:05 **Announcement winner Investors Forum**

---

16:20 **'What if our everyday objects are alive?'**  
 Ir. Bob Hendrixx, owner Studio Hendrixx | Loop Biotech

*Bob Hendrixx is exploring a living future. What if our everyday products are alive? We live in a world in which a dead tree has more value than a living tree. Let's change that. We strive for a fundamental new relationship with the natural world. What if we no longer work with dead materials, but with living organisms? Imagine buildings that grow, breathe and heal themselves. This talk takes you beyond the limits of your imagination by turning science-fiction into reality.*

---

17:00 **End of conference**

**Reception > exhibition open**

---

18:30 **End of the Dutch Life Sciences conference**

*Note: the organisation keeps the right to make changes to the programme at any time.*